A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Purpose
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.
Condition
- Alzheimer's Disease
Eligibility
- Eligible Ages
- Between 55 Years and 80 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Have a phosphorylated tau (P-tau) result consistent with the presence of amyloid pathology. - Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities. - Have adequate literacy, vision, and hearing for neuropsychological testing at screening. - Have a Mini Mental Status Exam (MMSE) score consistent with no to minimal cognitive impairment. - Have a Functional Activities Questionnaire (FAQ) score consistent with no to minimal functional impairment. - If currently receiving medications as symptomatic treatment for AD, dose has been stable for at least 30 days before screening.
Exclusion Criteria
- Have dementia or significant other neurological disease that can affect cognition. - Have current serious or unstable illnesses that in the investigator's opinion, could interfere with the analyses of the study. - Have a history of cancer that, in the investigator's opinion, has a high risk of recurrence. - Have a history of clinically significant multiple or severe drug allergies, or hypersensitivity reactions. - Have a clinically important laboratory test result or other abnormality as determined by investigator, prior to randomization, that could be detrimental to the participant or could compromise the study. - Have any contraindications for magnetic resonance imaging (MRI). - Have a centrally read MRI that does not meets study entry criteria. Prior or Current Therapies - Have ever had prior treatment with a passive anti-amyloid immunotherapy. - Have received active immunization against Aβ in any other study.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Remternetug |
Remternetug administered subcutaneously (SC). |
|
Placebo Comparator Placebo |
Placebo administered SC. |
|
Recruiting Locations
Birmingham, Alabama 35215
205-876-2601
Chandler, Arizona 85286
480-508-1038
Mesa, Arizona 85206
480-801-9260
Phoenix, Arizona 85006
602-839-6900
Tucson, Arizona 85718
520-694-7021
Fresno, California 93710
559-437-9700
Huntington Beach, California 92648
714-378-2440
Inglewood, California 90301
949-753-1663
Irvine, California 92614
949-753-1663
Long Beach, California 90804
562-606-5999
Riverside, California 92506
951-374-8000
Sacramento, California 95821
916-434-8230
San Diego, California 92103
619-915-0496
San Diego, California 92123
858-836-8350
San Francisco, California 94114
San Marcos, California 92069
Santa Ana, California 92705
714-542-3008
Santa Rosa, California 95403
707-290-1848
Sherman Oaks, California 91403
818-990-2671
Aurora, Colorado 80012
303-337-5707
Basalt, Colorado 81621
970-927-1141
Boulder, Colorado 80301
303-443-7229
Englewood, Colorado 80113
New Haven, Connecticut 06510
203-401-4300
Stamford, Connecticut 06905
203-914-1903
Atlantis, Florida 33462
Aventura, Florida 33180
305-933-5993
Bradenton, Florida 34205
941-708-0005
Clermont, Florida 34711
321-234-0199
Davie, Florida 33024
954-865-6144
Delray Beach, Florida 33445
561-374-8461
Fort Myers, Florida 33912
239-939-7777
Hialeah, Florida 33012
305-825-6588
Lady Lake, Florida 32159
352-500-5252
Maitland, Florida 32751
Maitland, Florida 32751
407-500-5252
Melbourne, Florida 32940
407-680-0534
Merritt Island, Florida 32952
Miami, Florida 33133
786-655-8010
Miami, Florida 33186
305-596-9901
Mount Dora, Florida 32757
352-383-8222
Naples, Florida 34105
239-529-6780
New Port Richey, Florida 34652
727-849-4131
Ocala, Florida 34470
352-629-5800
Orlando, Florida 32803
407-337-1000
Orlando, Florida 32804
407-303-6729
Pensacola, Florida 32504
850-438-1136
Port Orange, Florida 32127
386-304-7070
Stuart, Florida 34997
561-209-2400
Tampa, Florida 33609
813-353-9613
Tampa, Florida 33613
813-971-8311
Tampa, Florida 33625
855-339-1116
The Villages, Florida 32162
Wellington, Florida 33414
561-209-2400
West Palm Beach, Florida 33407
561-845-0500
Winter Park, Florida 32789
407-916-0060
Columbus, Georgia 31909
706-653-8455
Decatur, Georgia 30030
351-222-5383
Gainesville, Georgia 30501
770-534-5154
Woodstock, Georgia 30189
678-494-5735
Boise, Idaho 83704
208-685-0600
Chicago, Illinois 60611
Chicago, Illinois 60640
773-275-3500
Chicago, Illinois 60649
351-222-4915
Elk Grove Village, Illinois 60007
847-593-8553
Indianapolis, Indiana 46227
351-222-6663
Indianapolis, Indiana 46256
317-537-6099
Waterloo, Iowa 50701
319-888-8270
Topeka, Kansas 66606
785-354-9591
Lake Charles, Louisiana 70601
337-602-6642
Marrero, Louisiana 70072
Bangor, Maine 04401
207-973-6179
Baltimore, Maryland 21213
351-222-4915
Boston, Massachusetts 02116
617-934-5743
Boston, Massachusetts 02131
617-477-4868
Newton, Massachusetts 02459
617-699-6927
Quincy, Massachusetts 02169
650-796-1586
Waltham, Massachusetts 02451
617-744-1310
Watertown, Massachusetts 02472
617-744-8542
Dearborn, Michigan 48126
586-276-7453
Farmington Hills, Michigan 48334
248-957-8940
Saint Paul, Minnesota 55130
Hattiesburg, Mississippi 39401
601-579-5016
Bolivar, Missouri 65613
417-328-7781
Chesterfield, Missouri 63005
636-220-1200
Omaha, Nebraska 68198
402-559-9953
Las Vegas, Nevada 89128
702-750-000
Hoboken, New Jersey 07030
650-796-1586
Ridgewood, New Jersey 07450
973-850-4622
Springfield, New Jersey 07081
Toms River, New Jersey 08755
732-341-9500
Albuquerque, New Mexico 87109
505-848-3773
Charlotte, North Carolina 28210
351-222-5383
Greensboro, North Carolina 27405
336-763-6968
Monroe, North Carolina 28112
704-283-7359
Lima, Ohio 45805
351-222-6663
Middleburg Heights, Ohio 44130
Portland, Oregon 97210
503-279-8252
Philadelphia, Pennsylvania 19114
215-676-6696
Plymouth Meeting, Pennsylvania 19462
East Providence, Rhode Island 02914
401-435-8950
Providence, Rhode Island 02906
401-655-6403
Greenville, South Carolina 29607
Summerville, South Carolina 29485
843-569-1856
Cordova, Tennessee 38018
901-866-9252
Knoxville, Tennessee 37909
Austin, Texas 78757
512-407-8628
Beaumont, Texas 77702
409-331-6040
Dallas, Texas 75216
972-433-9100
Dallas, Texas 75231
972-433-9100
Georgetown, Texas 78633
737-279-4880
Houston, Texas 77054
351-222-6663
Houston, Texas 77054
713-486-0536
Houston, Texas 77057
832-460-3311
Rio Grande City, Texas 78582
Round Rock, Texas 78681
512-218-1222
San Antonio, Texas 78229
210-692-7157
Shavano Park, Texas 78231
210-545-4900
Arlington, Virginia 22206
650-796-1586
Fairfax, Virginia 22031
703-520-9703
Norfolk, Virginia 23510
757-446-5675
Bellevue, Washington 98007
425-453-0404
Renton, Washington 98057
425-251-1722
Bayamon, Puerto Rico 00961
(787) 798-4592
San Juan, Puerto Rico 00918
San Juan, Puerto Rico 00918
7877539515 ext 296
San Juan, Puerto Rico 00918
17874035534
More Details
- NCT ID
- NCT06653153
- Status
- Recruiting
- Sponsor
- Eli Lilly and Company
Study Contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or3176154559
clinical_inquiry_hub@lilly.com